NKG2D ligands, like UL16-binding proteins, can undergo altered expression in cancer through processes such as microRNA modulation, transcriptional regulation by factors like IFNγ, DNA methylation, or low histone acetylation (134–136). This evidence concerns the gene KLRK1 and cancer.